SARS Pneumonia Clinical Trial
— COVID-VENTOfficial title:
Respiratory Mechanics and Gas Exchange in Patients With COVID-19 and Hypoxemic Acute Respiratory Failure: Multicentral Observational Study
NCT number | NCT04445961 |
Other study ID # | COVID-VENT |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 1, 2020 |
Est. completion date | August 14, 2020 |
Verified date | June 2020 |
Source | I.M. Sechenov First Moscow State Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Data on respiratory mechanics and gas exchange in acute respiratory failure in COVID-19 patients is limited. Knowledge of respiratory mechanics and gas exchange in COVID-19 can lead to different selection of mechanical ventilation strategy, reduce ventilator-associated lung injury and improve outcomes. The objective of the study is to evaluate the respiratory mechanics, lung recruitability and gas exchange in COVID-19 -associated acute respiratory failure during the whole course of mechanical ventilation - invasive or non-invasive.
Status | Completed |
Enrollment | 117 |
Est. completion date | August 14, 2020 |
Est. primary completion date | August 14, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - all patients with COVID-19 and acute respiratory failure on invasive and noninvasive ventilation Exclusion Criteria: - Patients who reached the following goals at conventional oxygen therapy (oxygen flow < 15 l/min): peripheral capillary oxygen saturation(SpO2) > 93%, no visible work of auxiliary respiratory muscles, no fatigue, stable hemodynamics (no need in any catecholamines and/or life-threatening heart rhythm abnormalities), - less than 24 ours in intensive care unit (ICU) by any reason, - lung emphysema, - primary lung diseases (chronic obstructive lung disease-COPD, interstitial lung diseases, etc) or tumour metastases in lungs, - chronic decompensated diseases with extrapulmonary organ dysfunction (tumour progression, liver cirrhosis, congestive heart failure), - atonic coma. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Sechenov University Clinic #1 | Moscow | |
Russian Federation | Sechenov University Clinic #3 | Moscow | |
Russian Federation | Sechenov University Clinic #4 | Moscow |
Lead Sponsor | Collaborator |
---|---|
I.M. Sechenov First Moscow State Medical University |
Russian Federation,
Amato MB, Meade MO, Slutsky AS, Brochard L, Costa EL, Schoenfeld DA, Stewart TE, Briel M, Talmor D, Mercat A, Richard JC, Carvalho CR, Brower RG. Driving pressure and survival in the acute respiratory distress syndrome. N Engl J Med. 2015 Feb 19;372(8):747-55. doi: 10.1056/NEJMsa1410639. — View Citation
Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, Camporota L. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020 Jun;46(6):1099-1102. doi: 10.1007/s00134-020-06033-2. Epub 2020 Apr 14 — View Citation
Toufen Junior C, De Santis Santiago RR, Hirota AS, Carvalho ARS, Gomes S, Amato MBP, Carvalho CRR. Driving pressure and long-term outcomes in moderate/severe acute respiratory distress syndrome. Ann Intensive Care. 2018 Dec 7;8(1):119. doi: 10.1186/s13613 — View Citation
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Feb 7. doi: 10.100 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Optimum positive end-expiratory pressure (PEEP) level | Positive end-expiratory pressure (PEEP) selection at minimum level with maximum static compliance and the highest peripheral capillary oxygen saturation over fraction of inspired oxygen (SpO2/FiO2) | On day 1 during mechanical ventilation | |
Primary | Optimum positive end-expiratory pressure (PEEP) level | Positive end-expiratory pressure (PEEP) selection at minimum level with maximum static compliance and the highest peripheral capillary oxygen saturation over fraction of inspired oxygen (SpO2/FiO2) | On day 7 during mechanical ventilation | |
Primary | Number of patients with recruitable lung | Peripheral capillary oxygen saturation (SpO2) change from 90% after recruitment maneuver (doubled tidal volume for 15 respiratory cycles) - if peripheral capillary oxygen saturation (SpO2) after recruitment maneuver more than 95%-recruitable | On day 1 during mechanical ventilation | |
Primary | Number of patients with recruitable lung | Peripheral capillary oxygen saturation (SpO2) change from 90% after recruitment maneuver (doubled tidal volume for 15 respiratory cycles) - if peripheral capillary oxygen saturation (SpO2) after recruitment maneuver more than 95%-recruitable | On day 7 during mechanical ventilation | |
Secondary | Change in alveolar dead space | Calculation of the alveolar dead space using end-tidal carbon dioxide measurement and arterial carbon dioxide tension measurement | On day 1, 3, 5, 7, 10, 14, 21 during mechanical ventilation | |
Secondary | Change in plethysmogram variability during recruitment maneuver | Measurement of plethysmogram variability before and during recruitment maneuver | On day 1, 3, 5, 7, 10, 14, 21 during mechanical ventilation | |
Secondary | Change in arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio | Calculation of the arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio using arterial oxygen tension measurement | On day 1, 3, 5, 7, 10, 14, 21 during mechanical ventilation | |
Secondary | Optimum positive end-expiratory pressure (PEEP) level | Positive end-expiratory pressure (PEEP) selection at minimum level with maximum static compliance and the highest peripheral capillary oxygen saturation over fraction of inspired oxygen (SpO2/FiO2) | On day 3, 5, 10, 14, 21 during mechanical ventilation | |
Secondary | Change in driving pressure with different positive end-expiratory pressure (PEEP) levels | Driving pressure calculation at different positive end-expiratory pressure (PEEP) levels (8, 10, 12, 14) | On day 1, 3, 5, 7, 10, 14, 21 during mechanical ventilation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04584658 -
Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)
|
||
Withdrawn |
NCT04456426 -
Characteristics of Patients With COVID-19 in Meta State, Colombia
|
||
Terminated |
NCT04435457 -
Cardiovascular Implications of COVID-19
|
||
Completed |
NCT04621058 -
Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19.
|
Phase 3 | |
Terminated |
NCT04403685 -
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers
|
Phase 3 | |
Completed |
NCT04374565 -
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
|
Phase 2 | |
Completed |
NCT04405310 -
Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial
|
Phase 2 | |
Not yet recruiting |
NCT04393051 -
Baricitinib Compared to Standard Therapy in Patients With COVID-19
|
Phase 2 | |
Completed |
NCT04385901 -
Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth
|
N/A | |
Completed |
NCT04665960 -
Infection Control for Severe Acute Respiratory Syndrome Coronavirus 2
|
||
Completed |
NCT04629703 -
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
|
Phase 3 | |
Completed |
NCT04764422 -
Assess the Safety and Immunogenicity of NDV-HXP-S Vaccine in Thailand
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04315480 -
Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis
|
Phase 2 | |
Completed |
NCT04830800 -
A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC
|
Phase 1/Phase 2 | |
Terminated |
NCT04443673 -
Glycine Supplement for Severe COVID-19
|
N/A | |
Withdrawn |
NCT04459702 -
A Study of Combination Therapies to Treat COVID-19 Infection
|
Phase 2 | |
Recruiting |
NCT04753619 -
Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management
|
Phase 2 | |
Withdrawn |
NCT04395716 -
A Study of ResCureā¢ to Treat COVID-19 Infection
|
Phase 1 | |
Completed |
NCT04358640 -
Anxiety and Work Resilience Among Tertiary University Hospital Workers During the COVID-19 Outbreak: An Online Survey
|
||
Completed |
NCT04357340 -
The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19
|
N/A |